Invert Graphite Limited · ASX:IVG
Invert Graphite — Shareholder Meeting (July 2020)
17 slides from Invert Graphite's shareholder meeting presentation, Jul 30, 2020
Slide 1: Factor Therapeutics 2020 Annual General Meeting
Factor Therapeutics 2020 Annual General Meeting Chairman’s Address and Shareholder presentation on LONGMILE opportunity Brisbane (Australia), 30 July 2020: Factor Therapeutics Limited (ASX: FTT) is pleased to provide the Chairman’s Address to the 2020 Annual General Meeting of Shareholders being hel
Slide 2: Chairman's address: asset diligence and criteria
• clear scientific and technical rationale: the intellectual property and domain knowledge necessary for success • commercial potential: compelling target market size, product differentiation, competition, potential for reimbursement or a clear payor dynamic, and regulatory impediments • path to mar
Slide 3: Chairman's address: Long Mile transaction and timeline
The Long Mile transaction is complicated because it involves both the acquisition of a business unit, as well as establishing an ongoing manufacturing and innovation partnership with Long Mile’s parent company. Although we have completed much of the preliminary diligence and valuation analysis, ther
Slide 4: Longmile Opportunity
Longmile Opportunity AGM 2020 Factor Therapeutics Limited
Slide 5: Deal evaluation
Deal evaluation Criteria applied to new opportunities: 1. Unique and differentiated value proposition 30+ 2. At, or feasibly close, to generating commercial revenues 3. Minimal further development required; utility of technology established 4. Near-term commercial inflection points achievable with e
Slide 6: LONGMILE – Bringing PET imaging to vets
LONGMILE – Bringing PET imaging to vets LONGMILE has developed the world’s first portable, commercial PET (positron emission tomography) scanner optimized for veterinary use. Currently PET scanning is used almost extensively for human health: • Provides unique, 3D biological information • Function/a
Slide 7: Designed for vets – “PET for Pets”
Designed for vets – “PET for Pets” Human PET scanner LONGMILE’s MILE-PET® LONGMILE’s πPET® • Large installation footprint, $$$ • Completely portable • Completely portable • Not ideal for imaging animals • Designed for standing animals • No expensive infrastructure • $Bn market (CAGR 5-6%1) without a
Slide 8: MILE-PET scanner – optimised for equestrian sports
MILE-PET® scanner – optimised for equestrian sports LONGMILE’S MILE-PET scanner is designed to provide easy, safe PET scanning of horses for possible leg injuries: • Portable • Standing position, no anaesthesia • Imaging chamber opens and closes • Movement-compensating algorithms • Potential to expa
Slide 9: MILE-PET – provides unique and important information
MILE-PET – provides unique and important information Data from MILE-PET scans allows owners and vets to make more informed decisions regarding equine health: ✓ Measures and locates specific biological activities ✓ Provides high-resolution imaging data ✓ Can combine with structural data from X-ray, C
Slide 10: MILE-PET – Ready for commercial roll-out
MILE-PET – Ready for commercial roll-out Leading luminary sites are already using MILE-PET : • University of California Davis – School of Veterinary Medicine • Santa Anita Raceway (California, USA) • University of Pennsylvania – New Bolton Center ✓ Extensive field experience with >1000 scans conduct
Slide 11: πPET – Companion animal market for future growth
πPET® – Companion animal market for future growth The small size and portability of LONGMILE’s πPET device makes PET scanning readily available for the companion animal market As with humans, PET scans of companion animals are highly informative for: ✓ Cancer diagnosis / staging ✓ Surgical planning
Slide 12: πPET – Commercial release in 2H 2021
πPET – Commercial release in 2H 2021 PET technology provided in a format optimized for mainstream vet use: • Low cost, portable; opportunity to provide mobile imaging service • Specifically designed for use with companion animals • Unique IP to maximise image quality, deal with subject motion ✓ Adva
Slide 13: Building the team
Building the team David Beylin – Co-founder and current CEO • Will join the post-merger company as CEO • Ex-Program Director of Small Business Innovation at NIH, X/Seed Capital • Ex-Vice President of R&D at Naviscan PET Systems, Inc. • Board-certified Nuclear Medicine Physicist Australia-based GM an
Slide 14: Deal structure
Deal structure Proposed transaction • Acquisition of the LONGMILE division of Brain Biosciences, Inc. (parent company) • Initial diligence completed, detailed term sheet in place (deal structure, team, manufacturing, ongoing innovation plan, etc.) • Scrip-based acquisition: cash preserved to fund co
Slide 15: Transaction timelines
Transaction timelines Both parties committed to getting the deal done, high level of engagement • Negotiated exclusive, 120-day timeframe to conclude the transaction: • complete remaining due diligence matters • conclude deal structure, incorporating input from regulator • negotiate ancillary contra
Slide 16: Opportunity summary
Opportunity summary Unique, world-first – small footprint, portable PET scanner • MILE-PET® for equine injury assessment: ✓ First revenues, high profile exposure in elite performance market (the “Formula 1”) ✓ Equine application drives the technology • πPET® for companion animals (the “Prius”): ✓ Un
Slide 17: Questions
Questions